Cryofocus Medtech (Shanghai) Co. Ltd. Class H (HK:6922) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cryofocus Medtech (Shanghai) Co., Ltd. has released its interim financial results, reporting a revenue increase to RMB 19,475,000 for the first half of 2024, up from RMB 18,914,000 in the same period last year. Despite this, the company experienced a greater loss of RMB 55,953,000 compared to RMB 47,428,000 in the previous year, due to increased research and development expenses. The period was marked by significant progress in their product pipeline, including approvals and the initiation of clinical trials for various medical systems.
For further insights into HK:6922 stock, check out TipRanks’ Stock Analysis page.